16 May 2017, Melbourne, Victoria – Australian biotechnology company Aravax has commenced clinical trials of a potentially life-changing product developed to treat sufferers of peanut allergy. Aravax’s technology uses carefully selected fragments of peanut proteins to switch off allergic reactions. The product is designed to be safer, more rapid, and more convenient than other approaches currently under development. Aravax anticipates that simple, monthly injections will be sufficient to achieve clinical benefit. Pascal Hickey, CEO of Aravax, said, “We want to help people around the world who suffer from peanut allergy to live stress-free lives without constantly fearing a major health